Washington Statutes

§ 70.54.140 — Laetrile—Interference with physician/patient relationship by health facility—Pharmacy quality assurance commission, duties.

Washington § 70.54.140
JurisdictionWashington
Title 70PUBLIC HEALTH AND SAFETY
Ch. 70.54MISCELLANEOUS HEALTH AND SAFETY PROVISIONS

This text of Washington § 70.54.140 (Laetrile—Interference with physician/patient relationship by health facility—Pharmacy quality assurance commission, duties.) is published on Counsel Stack Legal Research, covering Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Wash. Rev. Code § 70.54.140 (2026).

Text

No hospital or health facility may interfere with the physician/patient relationship by restricting or forbidding the use of amygdalin (Laetrile) when prescribed or administered by a physician licensed pursuant to chapter 18.57 or 18.71 RCW and requested by a patient under his/her care who has requested the substance after having been given sufficient information in writing to make an informed decision. For the purposes of RCW 70.54.130 through 70.54.150 , the pharmacy quality assurance commission shall provide for the certification as to the identity of amygdalin (Laetrile) by random sample testing or other testing procedures, and shall promulgate rules and regulations necessary to implement and enforce its authority under this section.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

§ 70.54.130
Washington § 70.54.130

Legislative History

[2013 c 19 s 123;1977 ex.s. c 122 s 2.]

Nearby Sections

15
View on official source ↗

Cite This Page — Counsel Stack

Bluebook (online)
Washington § 70.54.140, Counsel Stack Legal Research, https://law.counselstack.com/statute/wa/70.54.140.